(NASDAQ: BOLD) Boundless Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.98%.
Boundless Bio's earnings in 2026 is -$58,197,000.On average, 5 Wall Street analysts forecast BOLD's earnings for 2026 to be -$54,776,766, with the lowest BOLD earnings forecast at -$55,117,356, and the highest BOLD earnings forecast at -$51,996,026. On average, 5 Wall Street analysts forecast BOLD's earnings for 2027 to be -$29,331,092, with the lowest BOLD earnings forecast at -$42,161,483, and the highest BOLD earnings forecast at -$20,469,024.
In 2028, BOLD is forecast to generate -$25,598,044 in earnings, with the lowest earnings forecast at -$34,256,205 and the highest earnings forecast at -$15,998,777.